Chimerix Receives FDA Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

News | 06. 04. 2021

Chimerix

DURHAM, N.C., June 04, 2021 — Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted TEMBEXA® (brincidofovir) tablets and oral suspension approval for the treatment of smallpox. TEMBEXA is approved for adult and pediatric patients, including neonates.